Leerink Partnrs Issues Positive Outlook for IRWD Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Leerink Partnrs increased their Q2 2026 earnings estimates for Ironwood Pharmaceuticals in a report issued on Monday, November 10th. Leerink Partnrs analyst F. Khurshid now forecasts that the biotechnology company will post earnings of $0.13 per share for the quarter, up from their previous estimate of $0.11. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.10 per share. Leerink Partnrs also issued estimates for Ironwood Pharmaceuticals’ Q3 2026 earnings at $0.15 EPS and Q4 2026 earnings at $0.25 EPS.

Several other equities analysts have also recently weighed in on the company. Wells Fargo & Company raised their price target on Ironwood Pharmaceuticals from $1.00 to $3.00 and gave the company an “equal weight” rating in a report on Tuesday. Weiss Ratings restated a “sell (e+)” rating on shares of Ironwood Pharmaceuticals in a research report on Wednesday, October 8th. Zacks Research lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Finally, Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 9th. One analyst has rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $5.34.

Ironwood Pharmaceuticals Stock Up 8.4%

Shares of Ironwood Pharmaceuticals stock opened at $3.37 on Wednesday. Ironwood Pharmaceuticals has a twelve month low of $0.53 and a twelve month high of $5.13. The business has a 50-day moving average price of $1.62 and a 200-day moving average price of $1.10. The firm has a market cap of $547.40 million, a price-to-earnings ratio of -67.39 and a beta of 0.37.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings results on Monday, November 10th. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.15. The company had revenue of $122.06 million for the quarter, compared to the consensus estimate of $74.22 million. Ironwood Pharmaceuticals had a negative net margin of 2.25% and a negative return on equity of 2.46%. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS.

Institutional Trading of Ironwood Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. Cerity Partners LLC bought a new stake in shares of Ironwood Pharmaceuticals during the 1st quarter worth approximately $142,000. CWM LLC grew its holdings in shares of Ironwood Pharmaceuticals by 801.1% in the first quarter. CWM LLC now owns 57,001 shares of the biotechnology company’s stock worth $84,000 after purchasing an additional 50,675 shares during the last quarter. Allianz Asset Management GmbH increased its stake in Ironwood Pharmaceuticals by 411.5% in the 1st quarter. Allianz Asset Management GmbH now owns 293,100 shares of the biotechnology company’s stock worth $431,000 after buying an additional 235,800 shares during the period. Y Intercept Hong Kong Ltd lifted its holdings in Ironwood Pharmaceuticals by 162.6% during the 1st quarter. Y Intercept Hong Kong Ltd now owns 39,782 shares of the biotechnology company’s stock valued at $58,000 after buying an additional 24,635 shares in the last quarter. Finally, KLP Kapitalforvaltning AS boosted its position in Ironwood Pharmaceuticals by 719.8% in the 1st quarter. KLP Kapitalforvaltning AS now owns 198,400 shares of the biotechnology company’s stock valued at $292,000 after buying an additional 174,200 shares during the period.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.